{"schema_version":"1.0","type":"article","title":"減重藥「第三名」爭奪戰：禮來 與 諾和諾德 之外，誰能成為下一個代謝巨頭？","url":"https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition.md","lang":"zh-Hant","date":"2026-06-22","publish_at":"2026-06-22T08:49:00+08:00","updated_at":"2026-06-22","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","臨床數據","生技投資","製藥巨頭"],"summary":"今年 ADA，也就是美國糖尿病學會年會，減重藥戰場又一次被點燃。","key_points":[],"facts":[],"sections":["01｜雙寡頭戰爭升級：注射劑之外，口服與多靶點才是下一輪主戰場","02｜第三名之爭的本質：不是複製 Lilly 或 Novo，而是找到自己的戰略窗口","03｜Pfizer：用 Berobenatide 搶月製劑窗口","04｜Roche：一手 Petrelintide，一手 Enicepatide，走的是雙軸策略","05｜AstraZeneca：Elecoglipron 不追最高減重，而是嵌入心腎代謝矩陣","06｜Regeneron：解決 GLP-1 做不到的事——肌肉流失","07｜中國創新力量上桌：不再只是跟隨者","結語｜下一場減重藥戰爭，不是找下一個 Tirzepatide，而是解決它還沒解決的問題"],"references":[{"title":"[1] Eli Lilly and Company","source":"Zepbound (tirzepatide) U.S. prescribing information:","date":"","url":"https://uspl.lilly.com/zepbound/zepbound.html#pi"},{"title":"[2] Novo Nordisk","source":"Wegovy U.S. prescribing information:","date":"","url":"https://www.novo-pi.com/wegovy.pdf"},{"title":"[3] Eli Lilly and Company","source":"Orforglipron phase 3 / oral GLP-1 investor information:","date":"","url":"https://investor.lilly.com/"},{"title":"[4] Pfizer","source":"Danuglipron and obesity pipeline investor information:","date":"","url":"https://www.pfizer.com/science/drug-product-pipeline"},{"title":"[5] Roche","source":"CT-388 / Carmot Therapeutics obesity pipeline investor information:","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-03-05"}],"images":[{"alt":"Facebook 原圖：減重藥「第三名」爭奪戰：禮來 與 諾和諾德 之外，誰能成為下一個代謝巨頭？（圖 1）","url":"https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition/facebook-01.png"},{"alt":"Facebook 原圖：減重藥「第三名」爭奪戰：禮來 與 諾和諾德 之外，誰能成為下一個代謝巨頭？（圖 2）","url":"https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition/facebook-02.png"},{"alt":"Facebook 原圖：減重藥「第三名」爭奪戰：禮來 與 諾和諾德 之外，誰能成為下一個代謝巨頭？（圖 3）","url":"https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition/facebook-03.png"},{"alt":"Facebook 原圖：減重藥「第三名」爭奪戰：禮來 與 諾和諾德 之外，誰能成為下一個代謝巨頭？（圖 4）","url":"https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition/cover-generated.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-22）。減重藥「第三名」爭奪戰：禮來 與 諾和諾德 之外，誰能成為下一個代謝巨頭？。https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-22-obesity-drug-third-place-competition-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}